FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499375061> ?p ?o ?g. }

• W2499375061 endingPage "507" @default.
• W2499375061 startingPage "501" @default.
• W2499375061 abstract "Purpose Combination therapy with dabrafenib and trametinib is safer and more effective than BRAF inhibitor-based monotherapy for metastatic melanoma. Methods We retrospectively analyzed BRAF-mutated metastatic melanoma patients treated at our institution with daily oral dabrafenib 300 mg and trametinib 2 mg from November 2013 to April 2016. This clinical record included both untreated and previously treated stage IV melanomas. Physical examination and laboratory examinations were performed monthly and disease re-evaluations were performed every 3 months. Results A total of 48 patients (24 male, 24 female) with BRAF-mutated metastatic melanoma received dabrafenib and trametinib; median age was 48 years (range 23-75). Median follow-up was 362.5 days (range 72-879). Best overall response rate consisted of 6.2% (3 patients) complete response, 64.6% (31) partial response, and 25% ( 12 ) stable disease; median time to best response was 11 weeks (range 5.7-125.5). Progression of disease was seen in 19 patients (39.6%), with median time to progression (TTP) of 26 weeks (range 8-54). A total of 15 patients (31.2%) died due to progression of disease. Median progression-free survival and median overall survival were not reached. To date, 30 patients (62.5%) are still under treatment. A total of 27 (56.2%) patients had at least one adverse event (AE); grade 3-4 AEs were seen in 4 cases (8.3%). The main toxicities were fever (25%), skin rash (14.6%), arthralgias (10.4%), and aspartate aminotransferase/alanine aminotransferase increase (8.3%). Treatment dose was reduced in 7 subjects (14.6%), with only one case of discontinuation due to AE. Conclusions Our data, using combined targeted therapy, are in line with the scientific literature in terms of both safety and effectiveness in a real-life setting." @default.
• W2499375061 created "2016-08-23" @default.
• W2499375061 creator A5000391768 @default.
• W2499375061 creator A5002892592 @default.
• W2499375061 creator A5027729250 @default.
• W2499375061 creator A5032506137 @default.
• W2499375061 creator A5040547128 @default.
• W2499375061 creator A5052353123 @default.
• W2499375061 creator A5073843172 @default.
• W2499375061 creator A5074487260 @default.
• W2499375061 creator A5084233190 @default.
• W2499375061 creator A5090903194 @default.
• W2499375061 date "2016-07-27" @default.
• W2499375061 modified "2023-09-25" @default.
• W2499375061 title "Combined Therapy with Dabrafenib and Trametinib in <i>BRAF</i>-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience" @default.
• W2499375061 cites W1506082933 @default.
• W2499375061 cites W1828732496 @default.
• W2499375061 cites W1965370740 @default.
• W2499375061 cites W1965480120 @default.
• W2499375061 cites W1967551644 @default.
• W2499375061 cites W2001710734 @default.
• W2499375061 cites W2093550507 @default.
• W2499375061 cites W2096387850 @default.
• W2499375061 cites W2109387929 @default.
• W2499375061 cites W2111131433 @default.
• W2499375061 cites W2118863192 @default.
• W2499375061 cites W2121545342 @default.
• W2499375061 cites W2128035403 @default.
• W2499375061 cites W2133075384 @default.
• W2499375061 cites W2135925159 @default.
• W2499375061 cites W2154748904 @default.
• W2499375061 cites W2160766792 @default.
• W2499375061 cites W2166662937 @default.
• W2499375061 cites W2214943066 @default.
• W2499375061 cites W2254594392 @default.
• W2499375061 cites W2319820520 @default.
• W2499375061 cites W2408782013 @default.
• W2499375061 cites W355051652 @default.
• W2499375061 doi "https://doi.org/10.5301/tj.5000539" @default.
• W2499375061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27470608" @default.
• W2499375061 hasPublicationYear "2016" @default.
• W2499375061 type Work @default.
• W2499375061 sameAs 2499375061 @default.
• W2499375061 citedByCount "6" @default.
• W2499375061 countsByYear W24993750612017 @default.
• W2499375061 countsByYear W24993750612019 @default.
• W2499375061 countsByYear W24993750612021 @default.
• W2499375061 countsByYear W24993750612022 @default.
• W2499375061 crossrefType "journal-article" @default.
• W2499375061 hasAuthorship W2499375061A5000391768 @default.
• W2499375061 hasAuthorship W2499375061A5002892592 @default.
• W2499375061 hasAuthorship W2499375061A5027729250 @default.
• W2499375061 hasAuthorship W2499375061A5032506137 @default.
• W2499375061 hasAuthorship W2499375061A5040547128 @default.
• W2499375061 hasAuthorship W2499375061A5052353123 @default.
• W2499375061 hasAuthorship W2499375061A5073843172 @default.
• W2499375061 hasAuthorship W2499375061A5074487260 @default.
• W2499375061 hasAuthorship W2499375061A5084233190 @default.
• W2499375061 hasAuthorship W2499375061A5090903194 @default.
• W2499375061 hasConcept C121608353 @default.
• W2499375061 hasConcept C126322002 @default.
• W2499375061 hasConcept C141071460 @default.
• W2499375061 hasConcept C143998085 @default.
• W2499375061 hasConcept C184235292 @default.
• W2499375061 hasConcept C197934379 @default.
• W2499375061 hasConcept C2776131300 @default.
• W2499375061 hasConcept C2776694085 @default.
• W2499375061 hasConcept C2777658100 @default.
• W2499375061 hasConcept C2778472372 @default.
• W2499375061 hasConcept C2778570526 @default.
• W2499375061 hasConcept C2778830669 @default.
• W2499375061 hasConcept C2780739268 @default.
• W2499375061 hasConcept C2994587330 @default.
• W2499375061 hasConcept C502942594 @default.
• W2499375061 hasConcept C57074206 @default.
• W2499375061 hasConcept C71924100 @default.
• W2499375061 hasConcept C86803240 @default.
• W2499375061 hasConcept C90924648 @default.
• W2499375061 hasConcept C95444343 @default.
• W2499375061 hasConceptScore W2499375061C121608353 @default.
• W2499375061 hasConceptScore W2499375061C126322002 @default.
• W2499375061 hasConceptScore W2499375061C141071460 @default.
• W2499375061 hasConceptScore W2499375061C143998085 @default.
• W2499375061 hasConceptScore W2499375061C184235292 @default.
• W2499375061 hasConceptScore W2499375061C197934379 @default.
• W2499375061 hasConceptScore W2499375061C2776131300 @default.
• W2499375061 hasConceptScore W2499375061C2776694085 @default.
• W2499375061 hasConceptScore W2499375061C2777658100 @default.
• W2499375061 hasConceptScore W2499375061C2778472372 @default.
• W2499375061 hasConceptScore W2499375061C2778570526 @default.
• W2499375061 hasConceptScore W2499375061C2778830669 @default.
• W2499375061 hasConceptScore W2499375061C2780739268 @default.
• W2499375061 hasConceptScore W2499375061C2994587330 @default.
• W2499375061 hasConceptScore W2499375061C502942594 @default.
• W2499375061 hasConceptScore W2499375061C57074206 @default.
• W2499375061 hasConceptScore W2499375061C71924100 @default.
• W2499375061 hasConceptScore W2499375061C86803240 @default.
• W2499375061 hasConceptScore W2499375061C90924648 @default.

• next